Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGS: LymphoStat-B For Lupus Not Like Failed Rituxan

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts cautiously optimistic the antibody candidate will succeed.

You may also be interested in...



HGS’ Lupus Candidate Demonstrates Efficacy In Three-Year Continuation Study

The biotech continues to aim for a 2010 BLA for LymphoStat-B, with Phase III data expected next year.

HGS’ Lupus Candidate Demonstrates Efficacy In Three-Year Continuation Study

The biotech continues to aim for a 2010 BLA for LymphoStat-B, with Phase III data expected next year.

HGS Invests In Oncology As Phase III Drugs Near Submission

Human Genome Sciences targets 2010 for Albuferon and LymphoStat-B launches.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel